TAVR poised for further market expansion-advisoryboard: At the recent 2013 American College of Cardiology (ACC) conference, experts debated the potential to expand TAVR indications to lower risk patients. Ultimately, panelists concluded that TAVR has strong potential for expansion to intermediate risk patients but should not be performed in low risk individuals.
Tuesday, March 26, 2013
TAVR poised for further market expansion
TAVR poised for further market expansion-advisoryboard: At the recent 2013 American College of Cardiology (ACC) conference, experts debated the potential to expand TAVR indications to lower risk patients. Ultimately, panelists concluded that TAVR has strong potential for expansion to intermediate risk patients but should not be performed in low risk individuals.
